References
- Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475–486.
- Craig CM, Schiller GJ. Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev 2008;22: 221–234.
- Deschler B, de Witte T, Mertelsmann R, . Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006;91:1513–1522.
- Detourmignies L, Wattel E, Lai JL, . Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases. Ann Hematol 1993;66:235–240.
- Kantarjian HM, Jeha S, Gandhi V, . Clofarabine: past, present, and future. Leuk Lymphoma 2007;48:1922–1930.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562–569.
- Raffoux E, Cras A, Recher C, . Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010;1:34–42.
- Lane S, Devinder G, McMillan NAJ, . Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma 2012;53:1077–.
- Corsetti MT, Salvi F, Perticone S, . Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res 2011;35:991–997.